Table I.
Patient demographics, tumor stage and NY-ESO-1 expression, HLA typing results, immunological and clinical summary
| Pt ID | Age | Sex | AJCC Stage | Prior therapy | HLA | Tumor NY-ESO-1 expression | Latest follow up (days) | Current disease status | NY-ESO-1 antibody | NY-ESO-1 CD4+ T resonses |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 59 | F | IIIB | Surgery | A1,A1,B57,B8,DR13,DR14,DQ5,DQ6,DP2,DP6 | N/A | 785 | NED | + | + |
| 2 | 76 | M | IIIB | Surgery | A11,A24,B18,B51,Cw1,Cw5,DR3,DR11,DQ2,DQ3,DP4,DP6 | − | 856 | R (827 d), RDF | − | + |
| 3 | 38 | M | IIIC | Surgery | A1,A33,B51,B56,C8,C8,DR4,DR7,DQ2,DQ3,DP2,DP5 | + (<5% of tumor cells) | 581 | R (456 d), LFU | + | − |
| 4 | 50 | F | IIB | Surgery | A3,A11,B44,B61,C2,C4,DR13,DR13,DQ6,DQ6DP4,DP34 | N/A | 709 | NED | + | + |
| 5 | 48 | F | IIIC | Surgery, Radiation | A24,A32,B39,B44,C7,C16,DR7,DR12,DQ3,DQ3,DP4,DP6 | N/A | 869 | NED | − | − |
| 6 | 62 | F | IIIB | Surgery | A11,A25,B13,B39,C6,C12,DR1,DR7,DQ2,DQ5,DP4,DP4 | N/A | 791 | R (123 d), RDF | + | + |
| 7 | 48 | F | IIB | Surgery | A1,A11,B18,B51,C5,C16,DR3,DR11,DQ2,DQ3,DP2,DP4 | − | 855 | NED | − | + |
| 8 | 51 | F | IIIA | Surgery | A1,A24,B13,B35,Cw4,Cw6,DR4,DR7,DQ2,DQ3,DP4, DP4 | N/A | 744 | NED | − | N/A |
| 9 | 56 | F | IIB | Surgery | A29,A68,B38,B51,DR1,DR7,DQ2,DQ5,DP2,DP2 | N/A | 764 | NED | − | + |
Pt ID patient identification number, NED no evidence of disease, R recurrence (at × days), RDF rendered disease-free following recurrence, LFU lost to follow up, + positive, − negative